PD-1/PD-L1 inhibitors provide an option after platinum in selected patients: objective responses occur in a minority, disease control in more, and signals are stronger in PD-L1–positive tumors despite low tumor mutational burden. The gene discussed is CD274; the disease is neoplasm.